Instrument Inactif

Communiqués BioCardia Inc Nasdaq

Actions

US09060U1016

Recherche biotechnologique et médicale

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

05/06	Les plus fortes hausses de la mi-séance	MT
05/06	BioCardia : la FDA confirme que l'essai CardiAMP HF II pourrait appuyer l'homologation de la thérapie cellulaire CardiAMP dans l'insuffisance cardiaque ischémique	CI

Communiqués

18/06	BioCardia Letter to Stockholders on 2026 Priorities and Strategic Opportunities	AQ
08/06	BioCardia Announces $4.4 Million Financing	AQ
05/06	FDA Confirms CardiAMP HF II May Support Premarket Approval of CardiAMP Cell Therapy for Ischemic HFrEF	AQ
28/05	BioCardia Announces Japan PMDA Record Of Advice Supports Regulatory Submission For Approval Of CardiAMP Cell Therapy For Ischemic Heart Failure	AQ
21/05	BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency	AQ
19/05	BioCardia to Participate in a Fireside Chat at the Alliance Global Partners (A.G.P) Healthcare Company Showcase	AQ
15/05	BioCardia Reports First Quarter 2026 Business Highlights and Financial Results	AQ
11/05	BioCardia to Host Q1 2026 Financial Results and Corporate Update Conference Call on May 15, 2026	AQ
08/05	BioCardia and FDA Align on Helix Transendocardial Delivery Catheter Clearance Pathways	AQ
28/04	BioCardia Announces Allowance of Japanese Patent on Proprietary Heart3D™ Fusion Imaging Software for Procedure Planning and Realtime Navigation During CardiAMP Cell Therapy Procedures	AQ
20/04	BioCardia and Japan PMDA Align on Acceptability of CardiAMP Clinical Data to Support Regulatory Approval in Ischemic Heart Failure	AQ
20/04	BioCardia : April 20, 2026 - BioCardia And Japan PMDA Align on Acceptability of CardiAMP Clinical Data to Support Regulatory Approval in Ischemic Heart Failure	PU
02/04	BioCardia Files Request for Meeting With FDA to Discuss Accelerated Approval Pathway for CardiAMP® System in Ischemic Heart Failure	AQ
24/03	BioCardia Reports 2025 Business Highlights and Financial Results	AQ
20/03	BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026	AQ
17/03	BioCardia Announces Pre-Submission Approval Package for Helix Transendocardial Delivery Catheter Accepted by FDA	AQ
03/03	BioCardia Late Breaking Echocardiography Clinical Results from CardiAMP HF Trial Presented at Technology and Heart Failure Therapeutics (THT)	AQ
10/02	BioCardia Files Pre-Submission for FDA Approval of Helix™ Transendocardial Delivery Catheter for Therapeutic and Diagnostic Agent Delivery to the Heart	AQ
03/02	BioCardia Announces Late Breaking Echocardiography Results from the CardiAMP HF Trial to be Presented at Technology and Heart Failure Therapeutics (THT)	AQ
16/12	BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA	AQ
03/12	BioCardia Announces Election of New Board Director, Marvin Slosman and Completion of Term for Outgoing Director, Dr. Richard Krasno	AQ
01/12	BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress	AQ
24/11	BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality	AQ
12/11	BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results	AQ
10/11	BioCardia Announces Henry Ford Health Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial	AQ